The drugmaker plans to acquire 33 percent stake in Avenue Therapeutics for $35 million at $6 per share, according to its stock exchange notification.
Shares of the pharmaceutical company fluctuated between gains and losses to trade at Rs 528.40.
Avenue Therapeutics shares currently trade at $4.16 in the U.S.
